Clinical Trial Detail

NCT ID NCT02286687
Title Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

Therapies

Talazoparib

Age Groups: senior adult

Additional content available in CKB BOOST